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TGF- Suppresses Tumor Progression in Colon Cancer
by Inhibition of IL-6 trans-Signaling
Introduction
Colorectal cancer is one of the most common fatal ma-
Christoph Becker,1,6 Massimo C. Fantini,1,6
Christoph Schramm,1 Hans A. Lehr,2 Stefan Wirtz,1
Alexei Nikolaev,1 Ju¨rgen Burg,2 Susanne Strand,1
lignancies worldwide, with an incidence second onlyRalf Kiesslich,1 Samuel Huber,1 Hiroaki Ito,3
to lung cancer. It develops in about 5% of the adultNorihiro Nishimoto,3 Kazuyuki Yoshizaki,3
population in the United States, and almost half of theseTadamitsu Kishimoto,3 Peter R. Galle,1
people will die as a consequence of the disease (WeirManfred Blessing,4 Stefan Rose-John,5
et al., 2003). However, the molecular pathogenesis ofand Markus F. Neurath1,*
colorectal cancer is still poorly understood. Several lines1Laboratory of Immunology
of evidence support an important role of TGF- in theI. Medical Clinic
development of colorectal cancer. For instance, muta-University of Mainz
tions of the TGF- receptor II are frequently observedLangenbeckstrasse 1
in patients with colon cancer, suggesting a potential role55131 Mainz
for TGF- in preventing colon carcinogenesis (Grady etGermany
al., 1999). Furthermore, inactivation of the Smad3 gene,2 Institute of Pathology
a downstream signaling molecule of the TGF- receptor,University of Mainz
may lead to the development of neoplastic lesions in55131 Mainz
the murine colon (Yang et al., 1999). However, the pre-Germany
cise role of TGF- signaling in colon carcinogenesis3 Osaka University
remains incompletely understood.Suita 565-0871
The cytokine interleukin (IL)-6 is a pleiotropic cytokineJapan
with a broad range of functions on immune and nonim-4 Center for Biotechnologies and Biomedicine
mune cells (for a review, see Naka et al., 2002). ClassicUniversity of Leipzig
signaling of IL-6 involves binding of IL-6 to target cellsDeutscher Platz 5
bearing the membrane bound IL-6 receptor. Alterna-
04103 Leipzig
tively, IL-6 can activate cells lacking the membrane
Germany
bound IL-6R when bound to a naturally occurring soluble5 Department of Biochemistry form of the IL-6 receptor (sIL-6R) in a process called
University of Kiel IL-6 trans-signaling (Jones et al., 2001). Functional stud-
24118 Kiel ies have demonstrated both pro- and anti-inflammatory
Germany roles of IL-6 (Naka et al., 2002). In addition, IL-6 has
been shown to promote hematopoiesis and terminal B
cell differentiation. Finally, recent data suggest a poten-
tial role of IL-6 in colon cancer. For instance, it has been
Summary shown that levels of IL-6 are increased in the serum of
patients suffering from colon carcinoma and correlated
Alterations of TGF- signaling have been described in with tumor size (Chung and Chang, 2003; Galizia et al.,
colorectal cancer, although the molecular conse- 2002). In addition, IL-6 has been shown to promote the
quences are largely unknown. By using transgenic growth of colon cancer epithelial cells in vitro (Schneider
mice overexpressing TGF- or a dominant-negative et al., 2000). However, the molecular and immunological
TGF-RII, we demonstrate that TGF- signaling in tu- mechanisms underlying these observations are largely
mor infiltrating T lymphocytes controls the growth of unknown.
dysplastic epithelial cells in experimental colorectal In the present manuscript we demonstrate a novel
cancer, as determined by histology and a novel system functional link between TGF- signaling in tumor infil-
for high-resolution chromoendoscopy. At the molecu- trating T cells and IL-6 trans-signaling for colon carcino-
lar level, TGF- signaling in T cells regulated STAT-3 genesis. Specifically, our data show that carcinogenesis
in the colon is highly dependent on TGF- production inactivation in tumor cells via IL-6. IL-6 signaling re-
tumor infiltrating T lymphocytes via a TGF--dependentquired tumor cell-derived soluble IL-6R rather than
mechanism controlling IL-6 trans-signaling.membrane bound IL-6R and suppression of such TGF-
-dependent IL-6 trans-signaling prevented tumor
progression in vivo. Taken together, our data provide Results
novel insights into TGF- signaling in colorectal can-
In order to investigate the functional role of TGF- sig-cer and suggest novel therapeutic approaches for
naling in colon carcinogenesis, we used a previouslycolorectal cancer based on inhibition of TGF--depen-
established murine colon carcinoma model (Okayasu etdent IL-6 trans-signaling.
al., 1996; Tanaka et al., 2003) based on the mutagenic
agent azoxymethan (AOM). Accordingly, FVB mice were
treated with AOM followed by three consecutive cycles*Correspondence: neurath@1-med.klinik.uni-mainz.de
6 These authors contribute equally to this work. of orally administrated dextran sulfate sodium (DSS)
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Figure 1. High-Resolution Mouse Chromoendoscopy for Monitoring of Colon Carcinogenesis
(A) Experimental procedure used to induce colon carcinomas in FVB mice. Mice were injected intraperitoneally with a single dose (7.4 mg/kg)
of the mutagenic agent azoxymethan (AOM) followed by three cycles of DSS in drinking water for 1 week and normal drinking water for 2 weeks.
(B) In vivo high-resolution endoscopy and chromoendoscopy of mice. Mice were anesthetized by intraperitoneal injection of avertine. Colon
mucosa was stained with methylene blue to visualize the crypt pattern.
(C) For histologic evaluation, biopsies were taken from lesions during routine endoscopy.
(D) Tumorigenesis in immunodeficient RAG-1 knockout and control mice. Five mice per group were treated as above in (A) and subjected to
endoscopy every week. In contrast to wild-type mice, large tumors could not be observed in RAG-1 knockout mice. One representative
endoscopic picture per group is shown.
over a period of 7 days (Figure 1A). To tightly monitor et al., 1999), we next determined TGF-R levels in AOM
plus DSS-treated mice. Interestingly, immunohistochemi-tumorigenesis in living mice in vivo, we developed a
high-resolution miniature endoscopic system for the cal staining of colon tumors showed downregulation of
TGF-RI expression on dysplastic epithelial cells asmurine colon (see Experimental Procedures). By using
this novel system and methylene blue-aided chromoen- compared to nondysplastic epithelial cells outside of
the tumor and epithelial cells from untreated mice (Fig-doscopy, we were able to detect aberrant crypt foci in
DSS plus AOM-treated wild-type FVB mice at day 15 ure 2A). In analogy to the situation in colorectal cancer in
humans, these data suggested that dysplastic epithelialbefore macroscopically visible lesions were seen by
conventional colonoscopy (Figure 1B). Small visible le- cells in AOM plus DSS-treated mice prevent TGF- sig-
naling by downregulating TGF-R levels.sions first appeared around day 20, which were followed
by the development of large tumors until day 80. Tumor Tumor-infiltrating cells in AOM plus DSS-treated mice
were found to be largely T cells (Figure 2A). Since tumorbiopsies taken during endoscopy showed high-grade
dysplasia and the presence of intraepithelial neoplasias cells in colorectal cancer are known to produce TGF-
(Coffey et al., 1986) and since TGF- induces its own(Figure 1C). To determine the role of T lymphocytes
in this model, we investigated tumor development in production in T cells (Seder et al., 1998), we hypothe-
sized that such tumor-infiltrating T cells could be animmunocompromised RAG-1 knockout mice. In con-
trast to wild-type mice, RAG-1 knockout mice did not important source of TGF-. Indeed, isolated tumor-infil-
trating T cells expressed large amounts of TGF- (Figuredevelop large tumors (Figure 1D), indicating that lym-
phocytes control tumor growth. 2B), suggesting that these cells contribute to TGF-
production in vivo. To further analyze the functional roleSince mutations of the TGF- receptor (TGF-R) have
been described in colorectal cancer in humans (Grady of TGF- production by T cells in this model of colon
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Figure 2. TGF- Signaling in T Cells Negatively Regulates Tumorigenesis
(A) Immunohistochemistry for TGF-R (left panels) and CD4 or CD8 (middle and right panels, respectively) on dysplastic and nondysplastic
tissue from DSS plus AOM treated wild-type mice was performed by using the TSA Cy3 and FITC systems. Cryosections were fixed in acetone.
Slides were then incubated with primary antibodies specific for TGFßRI or CD4/CD8, respectively. Before examination, the nuclei were
counterstained with Hoechst3342.
(B) TGF- production by tumor-infiltrating T cells. Tumor-infiltrating T cells and intestinal epithelial cells (IEC) were isolated from tumors of
wild-type mice and TGF- levels were determined by RT-PCR.
(C and D) Colon carcinogenesis in TGF- transgenic mice: TGF- was expressed under control of the CD2 promoter to achieve T cell
specific transgene expression. Ten mice were treated according to the above carcinogenesis protocol and monitored endoscopically and
macroscopically. Lesions were counted during endoscopy, and the differences between the wild-type and transgenic groups were statistically
significant (p  0.05). The results are expressed as mean values  SD (D). Time points of endoscopies are indicated on the x axis.
(E) Colon carcinogenesis in transgenic mice overexpressing a dominant-negative TGF- receptor under control of the CD2 promoter to achieve
T cell specific transgene expression. Ten mice were treated according to the carcinogenesis protocol and monitored endoscopically and
macroscopically. Transgenic mice showed markedly increased tumor size and number as compared to wild-type mice.
carcinogenesis, we therefore used transgenic mice over- larger tumors of wild-type mice at late stages of the
AOM plus DSS protocol expressed TGF-RI, suggestingexpressing TGF- under control of the CD2 promoter
in order to obtain a T cell specific expression of the that these cells prevent TGF- signaling in this TGF-
rich environment (Figure 2A). To determine the func-transgene (Figure 2C). The endoscopic scoring of such
TGF- transgenic mice subjected to the AOM/DSS pro- tional consequences of impaired TGF- signaling in
T cells for colorectal cancer, we next analyzed mice thattocol showed significant differences in terms of tumor
number and size of lesions in comparison to wild-type express a dominant-negative form of the TGFRII chain
in T lymphocytes under control of the CD2 promotermice (Figures 2C and 2D). Specifically, transgenic mice
overexpressing TGF- in T lymphocytes showed signifi- (Figure 2E). Compared to wild-type mice and TGF-
transgenic mice, the number of lesions observed incantly delayed development of intraepithelial neoplasias
and a smaller tumor size during the experimental proto- dnTGFRII transgenic mice was higher. In addition, the
size of the tumors in these mice was markedly larger,col when compared to their wild-type littermates indicat-
ing a protective role of TGF- production by tumor infil- resulting in the development of stenoses in the distal
colon and consecutive lethal ileus. Surviving mice sacri-trating T cells for development of colorectal cancer.
Interestingly, only few tumor-infiltrating T cells in ficed at the end of the experiment showed numerous
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large tumors of the colon (Figure 2E), further supporting proliferation of intestinal epithelial cells (IEC) (Tebbutt
et al., 2002). On the basis of these data, we next inves-a key regulatory role of TGF- signaling in T cells for
colon carcinogenesis. tigated a possible functional role of IL-6 in induc-
ing growth of dysplastic lesions in vivo. AccordinglyThe possibility that T cells play a central role in the
development of colon tumors led us to perform a screen- dnTGFRII transgenic mice subjected to AOM/ DSS
treatment received a weekly dose of 1 mg of a neutra-ing of the expression of T cell-derived cytokines in co-
lons and tumors of AOM plus DSS-treated wild-type and lizing antibody against the IL-6 receptor  chain. Mice
were again monitored by colonoscopy and chromo-transgenic animals. While neither interferon-, IL-4, IL-
10, or TNF- were significantly up- or downregulated in endoscopy. Interestingly, dnTGFRII transgenic mice
treated with the anti-IL-6R antibody were protected fromthese experiments (not shown), we found a markedly
higher expression of IL-6 in dnTGFRII transgenic mice colon carcinogenesis (Figure 4A). In particular, the aver-
age tumor number and size were significantly reducedwhen compared to wild-type and TGF- transgenic mice
(Figure 3A, left), suggesting that T cell-derived IL-6 could when compared to control transgenic mice (Figure 4B).
Thus, IL-6 receptor signaling is essential for colon carci-be responsible for the observed differences in colon
carcinogenesis between wild-type and transgenic mice. nogenesis in dnTGFRII transgenic mice. In further ex-
periments we tested the effects of anti-IL-6R antibodyTo verify these findings, we isolated spleen cells from
wild-type and transgenic animals and analyzed the su- treatment in wild-type mice. As demonstrated in Figure
4C, wild-type mice treated with the anti-IL-6R antibodypernatants of anti-CD3 plus anti-CD28 stimulated cells
for IL-6 levels by ELISA. As shown in Figure 3A (right), were also significantly protected from colon carcinogen-
esis. In particular, anti-IL-6R antibody treatment sup-cells from TGF- transgenic mice produced significantly
less IL-6 as compared to cells from wild-type mice, while pressed the growth of colon tumors. Thus, elevated IL-6
levels in wild-type mice contribute to tumor progressioncells from dnTGFRII transgenic mice produced signifi-
cantly more IL-6 as compared to cells from both wild- in experimental colon cancer.
In order to evaluate IL-6-dependent signal transduc-type and TGF- transgenic mice. Further studies using
bioptic sampling of tumors and normal tissue from wild- tion in the colon of AOM/DSS mice, immunohistochem-
istry for IL-6 receptor (IL-6R) expression was performed.type mice revealed a higher expression of IL-6 mRNA
in the tumor than in surrounding nondysplastic tissue Epithelial cells in the colon of untreated mice and non-
dysplastic epithelial cells in the colon of treated mice(Figure 3B). Additional time course experiments demon-
strated that IL-6 protein was strongly induced in colon showed strong staining for the IL-6R. Interestingly,
however, little or no IL-6R staining was noted in tumorlysates of wild-type mice during the development of
colon tumors (Figure 3C). Interestingly, augmented IL-6 lesions, indicating that dysplastic epithelial cells exhibit
greatly diminished surface expression of the membraneexpression started at day 20 when the first lesions be-
came detectable and coincided with the development bound IL-6R (Figure 5A). Moreover, dysplastic epithelial
cells exhibited strong nuclear staining for phospho-of colon tumors, thus suggesting a possible correlation
between IL-6 expression and tumor growth. STAT-3, a known intracellular target molecule of IL-6
signaling (Figure 5B). Western blotting for the IL-6R con-To analyze which cells in the lamina propria of tumors
contributed to the increased expression of IL-6, we iso- firmed the downregulation of the membrane bound IL-
6R chain during tumorigenesis in wild-type mice (Figurelated intestinal epithelial cells and lamina propria mono-
nuclear cells from a large number of tumors derived 5C). In spite of the downregulation of membrane bound
IL-6R on the tumor cell surface, however, RT-PCR ex-from wild-type mice and further purified these cells with
immunomagnetic beads for CD4, CD8, CD11c, and periments revealed that the mRNA for the membrane
bound IL-6 receptor is abundantly expressed in tumorB220. As shown in Figure 3D, tumor infiltrating CD4
T cells expressed IL-6, interferon- and TNF mRNA epithelial cells and, in fact, upregulated as compared to
normal colon epithelial cells or stroma cells (Figure 5D).implicating that the majority of CD4 T cells in the tumor
stroma exhibit an activated phenotype. IL-6 was also These data raised the possibility that tumor epithelial
cells are a major source for the soluble IL-6R (sIL-6R) byexpressed in tumor epithelial cells and dendritic cells,
whereas little IL-6 was found in the macrophage en- shedding membrane bound receptor from their surface.
Indeed, a second band of approx. 50 kDa correspondingriched population and CD8 T cells. TGF- was ex-
pressed by CD4 T cells, CD8 T cells, dendritic cells, to the soluble IL-6 receptor (sIL-6R) was strongly in-
duced during tumorigenesis (Figure 5C). Furthermore,and tumor epithelial cells, implicating possible autocrine
and paracrine TGF--dependent signaling pathways. Western blot analysis of concentrated supernatants
from tumor epithelial cells showed the presence of a 50Furthermore, immunofluorescence staining for IL-6 and
double staining for CD3 and IL-6 showed an overexpres- kDa band representing the soluble IL-6 receptor (Fig-
ure 5E).sion of IL-6 in the tumor stroma as compared to nondys-
plastic tissue and confirmed T lymphocytes as a major As the matrix metalloproteinase TNF- converting en-
zyme (TACE) is known to release soluble IL-6R by cleav-source of IL-6 expression in colonic tumor tissue (Figure
3E). Finally, we determined IL-6 secretion by CD4 age of membrane bound IL-6 receptor on the cell surface
(Jones et al., 2001), we next analyzed TACE expressionT cells isolated from tumors of wild-type mice (Figure
3F). In contrast to CD4 T cells isolated from normal on tumor epithelial cells. As shown in Figure 6A, TACE
was highly expressed on tumor epithelial cells as com-nondysplastic colon tissue, CD4 T cells isolated from
tumors secreted large amounts of IL-6 and such IL-6 pared to controls, suggesting that matrix metalloprotei-
nases such as TACE may control IL-6R shedding inproduction could be reduced by adding recombinant
TGF-. colon carcinogenesis. To further test this concept, we
used an organ culture system in which tumor tissue wasRecent data demonstrated that IL-6 could regulate the
The Role of sIL-6R in Colon Cancer
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Figure 3. IL-6 Is Highly Expressed by T Cells in the Tumor Stroma
(A) Left: Western blotting of tumors taken at day 80 of the experiment. Three representative tumors were taken from wild-type, TGF transgenic
or dnTGFRII transgenic mice. Tumors were lysed, and 30 g of protein was loaded on a 10% polyacrylamide gel. After transfer, membranes
were incubated with an antibody specific for IL-6. Right: ELISA for IL-6 levels in supernatants of isolated spleen cells from wild-type, TGF-
transgenic, or dnTGFRII transgenic mice upon stimulation with anti-CD3 plus anti-CD28 antibodies. The data represent three independent
experiments  SD (*p  0.05, **p  0.01).
(B) RT-PCR for IL-6 on biopsies taken from tumors or surrounding nondysplastic tissue in wild-type mice. Biopsies were frozen in liquid
nitrogen. RNA isolation and cDNA synthesis was performed as described in methods. Data show results from five tumors and three tumor-
free samples.
(C) Western blotting of colon samples taken at indicated time points throughout the course of the experiment in wild-type mice. Experimental
procedures were as described above.
(D) RT-PCR for different cytokines of purified intestinal epithelial cells (IEC), LP CD4 and CD8 T cells, CD11c cells, B220 B cells, and
macrophage-enriched cells (MO) from tumors of wild-type mice. RNA isolation and cDNA synthesis was performed as described in the
Experimental Procedures.
(E) Immunohistochemistry for IL-6 was performed with the TSA Cy3 and FITC system. Cryosections of tumor and tumor-free samples were
fixed in acetone. Slides were then incubated with primary antibodies specific for IL-6 or CD3. The nuclei were counterstained with Hoechst3342.
(F) IL-6 production by 2  105 mock or TGF- (10 ng/ml) treated CD4 T cells or CD4 negative mononuclear cells isolated from tumors or
tumor-free control tissue obtained from wild-type mice. A second independent experiment gave similar results.
coincubated with an inhibitor of matrix metalloprotei- Therefore, we injected a daily dose of hyper-IL-6, a de-
signer cytokine consisting of IL-6 and a covalently linkednases (TAPI-TNF- protease inhibitor) followed by anal-
ysis of membrane bound IL-6R expression. Interestingly, soluble IL-6 receptor (Fischer et al., 1997), for 1 week into
dnTGFRII mice. Biopsies were taken from the sameTAPI treatment led to a marked upregulation of the ex-
pression of membrane bound IL-6 receptor on the tumor tumors before and after hyper-IL-6 treatment. Indeed,
mice that received hyper-IL-6 displayed a stronger pro-cell surface (Figure 6B). These data suggested that ma-
trix metalloproteinases induce a shift from membrane liferation of dysplastic epithelial cells as measured by
counting KI-67 positive cells (Figure 6C; left panels).bound IL-6R expression on the tumor cell surface to-
ward release of soluble IL-6R, thereby allowing IL-6 Furthermore, epithelial cells in hyper-IL-6 treated ani-
mals showed a stronger nuclear staining of phospho-trans-signaling.
Next, we investigated whether IL-6 trans-signaling STAT-3 (Figure 6C; right panels). Finally, specific block-
ade of signaling via the sIL-6R using gp130-Fc sup-could induce proliferation of dysplastic epithelial cells.
Immunity
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Figure 4. Blocking IL-6 Receptor Signaling Interferes with Colon Carcinogenesis in Wild-Type Mice and Mice Carrying a Dominant-Negative
TGF- Receptor in T Cells
Wild-type (C) and dnTGFRII transgenic mice (A and B) were treated with azoxymethane and DSS to induce colon carcinogenesis. Ten
dnTGFRII transgenic and ten wild-type mice were separated into two groups. One group received a weekly dose of a neutralizing antibody
against the IL-6 receptor  chain by intraperitoneal injection. The other group was injected with PBS as a control. Tumor development was
monitored by endoscopic screening of the mice at indicated time points upon AOM administration (A). Tumors were counted and average
tumor scores were compared between the groups (B and C). *p  0.05.
pressed colon carcinogenesis in dnTGFVRII mice (Fig- regulation of tumor cell growth by tumor infiltrating lym-
ure 6D) implicating IL-6 trans-signaling via the sIL-6R phocytes. Furthermore, blockade of IL-6 trans-signaling
as being responsible for epithelial cell growth in tumor emerges as a novel therapeutic approach for colo-
lesions. Thus, IL-6 trans-signaling is essential for colon rectal cancer.
carcinogenesis in dnTGFVRII mice and can induce phos- IL-6 is a cytokine involved in numerous functions
phorylation of STAT-3 and cell cycle progression in dys- within the immune system (Glimcher and Murphy, 2000;
plastic IEC. Taken together, our data indicate that IL-6 Hurst et al., 2001; Jones et al., 2001; Murphy and Reiner,
trans-signaling triggers the growth of dysplastic epithe- 2002; Naka et al., 2002; Rengarajan and Szabo, 2000)
lial cells and that this cascade can be modulated by and there is growing evidence that it is involved in normal
TGF- signaling in tumor infiltrating T cells. development of the intestinal epithelium. In fact, recent
data indicate that IL-6 regulates the proliferation of in-
testinal epithelial cells (IEC) (Tebbutt et al., 2002). FurtherDiscussion
findings implicate a role for IL-6 in the pathogenesis of
colon cancer: IL-6 serum levels have been shown to beIn the present manuscript, we have identified a novel
strongly elevated in patients with colon cancer and weremechanism whereby tumor infiltrating T lymphocytes
correlated to the tumor load suggesting the use of IL-6control tumor growth in a murine model of colon cancer.
serum levels as a prognostic factor in colorectal cancerSpecifically, we found that TGF- production in tumor
(Chung and Chang, 2003; Galizia et al., 2002). Further-infiltrating T lymphocytes suppresses tumor growth in
more, IL-6 has been shown to enhance colony formationthe colon via inhibition of IL-6 production and subse-
of human colon carcinoma cells in vitro in a dose-depen-quent IL-6 signal transduction. Interestingly, IL-6 signal
dent manner, suggesting that IL-6 may drive cancertransduction was mediated by the soluble rather than
growth (Schneider et al., 2000).the membrane bound IL-6R, indicating that tumor
TGF- has been shown to suppress Th2 cytokine pro-growth is controlled by IL-6 trans-signaling via the solu-
duction via inhibition of key transcription factors suchble form of the IL-6R. Such TGF--dependent IL-6
trans-signaling provides a molecular explanation for as STAT-6 and GATA-3 (Heath et al., 2000). The findings
The Role of sIL-6R in Colon Cancer
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Figure 5. The Soluble IL-6 Receptor, but Not the Membrane Bound Receptor, Is Strongly Expressed in Colon Tumors
(A and B) Immunohistochemistry for the IL-6 receptor (A) and phospho-STAT-3 (B) was performed with the Cy3 and FITC systems, respectively.
Cryosections of colon tumors from DSS plus AOM-treated wild-type mice and colonic tissue from untreated control mice were fixed in acetone.
Slides were then incubated with primary antibodies specific for the IL-6 receptor or phospho-STAT-3. Before examination, the nuclei were
counterstained with Hoechst3342.
(C) Western blot for the IL-6 receptor  chain and the sIL-6R. Colon samples from wild-type mice were taken on days 0, 7, 21, 28, and 42 of
the experiment. Tissue was lysed with a homogenizer, and 30 g of each sample was loaded on a polyacrylamide gel. After transfer onto
nitrocellulose, the membrane was incubated with an antibody specific for the IL-6 receptor. As a control, membranes were probed with an
antibody against the housekeeping gene ERK-2.
(D) RT-PCR for the IL-6R  chain was performed by using cDNA from purified cells derived from tumors (T) and tumor-free control tissue (N)
of wild-type mice. Intestinal epithelial cells (IEC), CD4 T cells, CD11c cells, CD8 T cells, B220 B cells, and macrophage-enriched cells
(MO) were isolated as described in the Experimental Procedures.
(E) Western blot with supernatants of tumor epithelial cells cultured for 24 hr in serum-free medium. Supernatants were concentrated by using
acetone precipitation, and 50 g of protein sample was loaded on a polyacrylamide gel. The membrane was probed with an antibody specific
for the IL-6 receptor  chain. A strong band at 50 kDa corresponding to the sIL-6R was seen.
in the present manuscript suggest that TGF- signaling lead to sIL-6R production and subsequent sIL-6R-
dependent tumor growth. Consistent with a role for ma-in tumor infiltrating T cells regulates IL-6 production in
colorectal cancer. Furthermore, we observed that sup- trix metalloproteinases in controlling tumor progression,
TACE is known to activate epidermal growth factor (EGF)pression of TGF- signaling in T cells of transgenic mice
expressing a dominant-negative TGF- receptor II led ligands such as TGF- and thereby controls EGFR-
dependent growth of breast tumor cells in vivo (Borrell-to an augmented and accelerated tumor cell growth
in vivo in an IL-6-dependent fashion. IEC-derived tumor Pages et al., 2003; Sunnarborg et al., 2002).
Subsequent studies showed that the growth of IEC-cells produced large amounts of IL-6R mRNA but lacked
the membrane bound IL-6R. Organ culture studies derived tumor cells was dependent on IL-6 trans-signal-
ing via the sIL-6R. Such IL-6 trans-signaling has recentlyshowed that this finding was due to shedding of the
membrane bound IL-6R on tumor cells with subsequent emerged as the molecular consequence of heat re-
sponses in T cells and plays a pivotal role in amplificationrelease of the soluble IL-6R (sIL-6R) via matrix metallo-
proteinases. Furthermore, the matrix metalloproteinase of immune responses during fever reactions (Chen et
al., 2004; Rose-John and Neurath, 2004). Furthermore,TACE, which is known to induce IL-6R shedding (Jones
et al., 2001), was upregulated in tumor cells suggesting it has been previously shown to induce chronic inflam-
mation and mediates recruitment of leukocytes to in-a model in which proteases produced by tumor cells
Immunity
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Figure 6. The sIL-6R Induces Phospho-STAT-3 and KI-67 Expression in Dysplastic Epithelial Cells
(A) Immunohistochemistry for TACE expression on tumor epithelial cells (upper right) as compared to tumor-free tissue (upper left) from wild-
type mice.
(B) Detection of the membrane bound IL-6 receptor  chain expressed on the surface of tumor epithelial cells. Organ culture of tumor tissue
was performed in the presence or absence of the matrix metalloproteinase inhibitor TAPI, as indicated. TAPI treatment led to a marked
upregulation of IL-6R expression on tumor cells.
(C) Biopsies from wild-type mice were taken during endoscopy of three individual tumors at day 80 of the experiment. The same mice were
then intraperitoneally injected daily with 2 g of hyper-IL6 (designer cytokine consisting of IL-6 and sIL-6R) to induce IL-6 trans-signaling.
Biopsies were then taken from the same tumors, as shown by video endoscopy. Biopsies were frozen in liquid nitrogen. Cryosections of
these biopsies from the same tumors before and after hyper-IL-6 treatment were subjected to immunohistochemistry for KI-67 (left panels)
and phospho-STAT-3 (right panels). Hyper-IL-6 treatment induced STAT-3 phosphorylation and proliferation of colonic tumors in vivo. (D)
AOM plus DSS-treated dnTGFbRII transgenic mice were treated with gp130-Fc to block IL-6 trans-signaling in vivo. Endoscopic monitoring
showed suppression of tumorigenesis upon administration of gp130-Fc.
flammatory lesions in vivo (Atreya et al., 2000; Hurst et coincided with the appearance of lesions in these ani-
mals and the activation of the IL-6-dependent transcrip-al., 2001; Romano et al., 1997; Rose-John and Heinrich,
1994). Hereby, IL-6 trans-signaling induced STAT-3 acti- tion factor STAT-3 (Akira, 2000; Neurath et al., 2002) in
dysplastic epithelial cells. Furthermore, suppression ofvation and production of the anti-apoptotic proteins bcl-
xl and bcl-2 in T cells. Furthermore, it induced expres- IL-6 signal transduction via anti-IL-6R antibodies pre-
vented tumor growth in wild-type and transgenic mice.sion of adhesion molecules such as L-selectin, resulting
in increased adhesion of T lymphocytes. These findings demonstrated that the effects upon
blockade of TGF- signaling in T cells are critically depen-In addition to the previously described role of IL-6
trans-signaling in acute and chronic inflammatory re- dent on IL-6 signal transduction. Finally, the trans-sig-
naling mechanism of action was revealed operationallysponses, our data define a novel role for such signaling
in the control of cancer growth. A role for the trans- by the finding that treatment of animals with gp130-
Fc (which inhibits signaling via the sIL-6R, but not thesignaling mechanism of action was implicated by the
finding that mice treated with DSS/azoxymethan showed membrane bound IL-6R) suppressed cancer growth
in vivo. These findings provide strong evidence that sig-increased levels of soluble IL-6 receptor around day
20 of the experiment and such increased expression naling via the soluble rather than the membrane bound
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buffer. After boiling, the proteins were separated by 10% SDS-IL-6R controls tumor growth in vivo and allow novel
PAGE, then transferred to nitrocellulose membranes and detectedinsights into the molecular pathogenesis of colon
with a specific antibody against IL-6, ERK-2, -actin (Santa Cruzcancer.
Biotechnology, Santa Cruz, California), or IL-6R alpha (MR-16-1;
Tumor infiltrating T lymphocytes have been associ- kindly donated by Chugai Pharmaceuticals, Shizuoka, Japan and
ated with a better prognosis of colorectal cancer (Fu- Santa Cruz Biotechnology) and the ECL Western blotting analysis
system (Amersham).nada et al., 2003). Our data suggest that TGF- pro-
duction in tumor infiltrating T lymphocytes strongly
ELISAsuppresses tumor growth in the colon via inhibition of
Cells were seeded at a concentration of 1,000,000 cells/ml (spleenIL-6 production by T cells in an autocrine or paracrine
cells) or 200,000 cells/ml (tumor-infiltrating T cells). After 24 hr super-fashion, thereby providing a novel mechanism for regu-
natants were taken for ELISA. For the detection of IL-6 in superna-
lation of tumor cell growth by tumor-infiltrating lympho- tants, an ELISA kit was used (R&D Systems) according to the manu-
cytes. In contrast, suppression of TGF- signaling in facturer’s instructions.
these cells augmented and accelerated tumor cell
growth in an IL-6-dependent fashion. IEC-derived tumor Isolation and Culture of Tumor-Infiltrating Cells
and Spleen Cellscells lacking the membrane bound IL-6R were depen-
Lamina propria mononuclear cells (LPMC) were isolated as follows:dent on IL-6 trans-signaling via the sIL-6R. The potential
the colon was opened longitudinally and washed several times inrelevance of these findings for human colorectal cancer
PBS to remove feces and debris. Tumors and tumor-free colon
is highlighted by the findings that a large subgroup of pieces were incubated at 37	C in PBS supplemented with 0.145
colorectal cancers shows decreased expression of the mg/ml DTT and 0.37 mg/ml EDTA for 15 min to separate epithelial
cells. The tissue was then digested in RPMI 1640 containing 0.15membrane-bound IL-6 receptor but increased expres-
mg/ml type II collagenase (Worthington, Munich, Germany) and 0.1sion of the sIL-6R (C.B., M.C.F., and M.F.N., unpublished
mg/ml DNase (Roche Molecular Biochemicals, Mannheim, Ger-data). Interestingly, it has been recently suggested that
many) for 75–90 min at 37	C on a shaking platform. CD4 T, CD8the sIL-6R controls the adherence of colon tumor cells
T, and B220 B lymphocytes as well as CD11c dendritic cells were
to the vascular endothelium, thereby supporting the for- subsequently isolated by using microbeads and MACS techniques
mation of metastases (Dowdall et al., 2002). Thus, the (Miltenyi Biotech, Bergisch-Gladbach, Germany). Remaining cells
were used as macrophage-enriched fraction. In addition, spleensoluble IL-6 receptor emerges a key molecule at differ-
cells were isolated as previously described (Atreya et al., 2000).ent stages of colon cancer pathogenesis. Furthermore,
Tumor epithelial cells and T cells were incubated in X-vivo 15 (Biotargeting of the sIL-6R and IL-6 trans-signaling can be
Whittaker). In some experiments, recombinant murine TGF- wasused for therapy of colon cancer.
added at a concentration of 10 ng/ml.
In Vitro Organ Culture
Experimental Procedures Intestinal tumors were dissected from the colon of mice after 80
days of DSS/AOM treatment. The tumors were cut in two parts (2–3
Animals mm) and placed on steel grids in an organ culture chamber at 37	C
Specific pathogen free FVB/N, C57 BL/6 and RAG-1 knockout mice in a 5% CO2/95% O2 atmosphere in complete RPMI1640 medium.
(2–4 months old) were obtained from the central animal facility TAPI (TNF protease inhibitor; obtained from Calbiochem, San
(ZVTE, University of Mainz, Germany). To induce colon carcinomas, Diego, CA) was added to a final concentration of 50 M. After 24
mice were injected intraperitoneally with a single dose (7.4 mg/kg) hr, tumor specimens were collected and frozen in OCT compound
of the mutagenic agent azoxymethane (AOM) followed by three for subsequent immunohistochemical analysis.
cycles of 3% dextran sodium sulfate (DSS) in drinking water for 1 Isolation of mRNA and RT-PCR
week and normal drinking water for 2 weeks. Transgenic mice were Total RNA was isolated with the High Pure RNA isolation kit (Roche)
generated as previously described (Schramm et al., 2003). In some according to the manufacturer’s recommendations. Reverse tran-
experiments, mice were given weekly doses (1 mg) of antibody scription into cDNA was performed with the Superscript II Reverse
against mouse IL-6R (MR-16-1; kindly donated by Chugai Pharma- Transcriptase kit (Invitrogen) according to the manufacturer’s rec-
ceuticals, Shizuoka, Japan), 500 g gp130-Fc, or phosphate buf- ommendations. PCR was performed by using the following primers
fered saline (PBS), by intraperitoneal injection. derived from previously published sequence data: murine IL-6, 5
-
ACACACTGGTTCTGAGGGAC-3
 and 5
-TACCACAAGGTTGGCAG
GTG; murine TGF1, 5
-TGCTGCTTTCTCCCTCAACCT-3
 and 5
-CACEndoscopic Procedures
TGCTTCCCGAATGTCTGA-3
; murine IFN-, 5
-ACACTGCATCTTGFor the continuous monitoring of tumorigenesis, a high-resolution
GCTTTGC-3
 and 5
-CGGATGAGCTCATTGAATGCT-3
; murinemouse video endoscope, denoted Coloview, was developed (2 mm
TNF, 5
-AACTGGCAGAAGAGGCACTC-3
 and 5
-TTGGGCAGATTouter diameter). Mice were anesthetized by intraperitoneal injection
GACCTCAGC-3
; murine IL-6R, 5
-ACACACTGGTTCTGAGGGAC-of avertine (Sigma Chem., St. Louis). The experimental setup con-
3
 and 5
-TACCACAAGGTTGGCAGGTG-3
; -actin, 5
-TGACGGGsisted of a miniature endoscope, a xenon light source, and an air
GTCACCCACACTGTGCCCATCTA-3
 and 5
-CTAGAAGCATTTGCpump to achieve a regulated inflation of the mouse colon. The endo-
GGTGGACGATGGAGGG-3
. PCR products were analyzed on 1%scopic procedure was viewed on a color monitor and digitally re-
agarose gels.corded on tape by using a triple chip camera. This novel technique
was combined with a whole colon chromoendoscopic staining with
methylene blue in order to visualize the crypt pattern and to detect Histologic Analysis of Colon Cross-Sections
aberrant crypt foci in vivo. Therefore, the colon was flushed with Tissues were removed from mice and sections were made and
500l of a 1% solution of methylene blue by using a syringe mounted stained with hematoxylin and eosin. The degree of dysplasia on
to the Luer lock cones of the examination sheath of the endoscope. microscopic cross-sections of the colon was graded by the same
Tumor sampling in living mice was performed by taking biopsies pathologist (H.A.L.) in a blinded fashion.
that were then frozen immediately in liquid nitrogen.
Immunohistochemistry
Immunofluorescence was performed by using the TSA Cy3 and FITCWestern Blot Analysis
Western blotting was performed as previously described (Becker systems (Perkin Elmer) and a fluorescence microscope (Olympus,
Melville, NY) (Becker et al., 2003). In brief, cryosections were fixedet al., 2003). In some experiments, culture supernatants were used
and concentrated by acetone precipitation. Equal amounts of ex- in ice-cold acetone for 10 min followed by sequential incubation
with methanol, avidin/biotin (Vector Laboratories, Burlingame, CA),tract (30 or 50 g) were added to 10 l electrophoresis sample
Immunity
500
and protein blocking reagent (DAKO, Wiesbaden, Germany) to elimi- Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J.P., Kallen,
K.J., Wollmer, A., Grotzinger, J., and Rose-John, S. (1997). A bioac-nate unspecific background staining. Slides were then incubated
overnight with primary antibodies specific for CD4, CD3, CD8, tive designer cytokine for human hematopoietic progenitor cell
expansion. Nat. Biotechnol. 15, 142–145.pSTAT-3, IL-6, IL-6R alpha, TGFRI, TACE (all from Santa Cruz), or
KI-67 (DAKO). Subsequently, the slides were incubated for 30 min at Funada, Y., Noguchi, T., Kikuchi, R., Takeno, S., Uchida, Y., and
room temperature with biotinylated secondary antibodies (Dianova, Gabbert, H.E. (2003). Prognostic significance of CD8 T cell and
Darmstadt, Germany). All samples were finally treated with strep- macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep.
tavidine-HRP and stained with Tyramide (Cy3 or FITC) according 10, 309–313.
to the manufacturer’s instructions (PerkinElmer, Heidelberg, Ger-
Galizia, G., Orditura, M., Romano, C., Lieto, E., Castellano, P., Pelo-
many). Before examination, the nuclei were counterstained with
sio, L., Imperatore, V., Catalano, G., Pignatelli, C., and Vita, F.D.
Hoechst3342 (Molecular probes, Eugene, OH).
(2002). Prognostic significance of circulating IL-10 and IL-6 serum
levels in colon cancer patients undergoing surgery. Clin. Immunol.
Construction of gp130-Fc and Preparation of Hyper-IL-6 102, 169–178.
The gp130-Fc fusion protein was made by linking cDNA coding for
Glimcher, L.H., and Murphy, K.M. (2000). Lineage commitment inthe extracellular portion of human gp130 to cDNA coding for the Fc
the immune system: the T helper lymphocyte grows up. Genes Dev.portion of human IgG1. gp130-Fc was expressed in COS-7 cells
14, 1693–1711.or stably transfected CHO cells and was purified with protein A
Grady, W.M., Myeroff, L.L., Swinler, S.E., Rajput, A., Thiagalingam,sepharose followed by gel filtration (Atreya et al., 2000). Hyper-IL-6
S., Lutterbaugh, J.D., Neumann, A., Brattain, M.G., Chang, J., Kim,was made, as previously described (Fischer et al., 1997).
S.J., et al. (1999). Mutational inactivation of transforming growth
factor beta receptor type II in microsatellite stable colon cancers.Statistical Analysis
Cancer Res. 59, 320–324.Data were analyzed by the Student’s t-test with the program Micro-
Heath, V.L., Murphy, E.E., Crain, C., Tomlinson, M.G., and O’Garra,soft Excel.
A. (2000). TGF-beta1 down-regulates Th2 development and results
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